Secondary Logo

Journal Logo

February 1992 - Volume 11 - Issue 2
pp: 77-153

PDF Only



PDF Only


COMBINED IMMUNOLOGIC THERAPY WITH INTERLEUKIN-2 AND ANTI-GD-2 MONOCLONAL ANTIBODY 14.G2a INDUCES IN VIVO IMMUNOLOGIC CONDITIONS ABLE TO MEDIATE ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY (ADCC) IN VITRO, IN PEDIATRIC NEUROBLASTOMA PATIENTS

Hank, J. A.; Surfus, J.; Gan, J.; More

Journal of Immunotherapy. 11(2):126, February 1992.

PHASE I TRIAL OF MURINE ANTI-GANGLIOSIDE (GD2) MONOCLONAL ANTIBODY (Mab) 14G2A IN CANCER PATIENTS

Murray, J. L.; Cunningham, J. E.; Brewer, H. M.; More

Journal of Immunotherapy. 11(2):135, February 1992.

Show: